Licensing

Anthrocell pursues a deliberate strategy of early international exposure aimed at establishing strategic alliances with companies developing novel biological products, specifically monoclonal antibodies, or companies looking to improve the spectrum or performance of already existing biological products, as well as manufacturers of biological products.

Please contact us with expressions of interest or requests for further information.